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Abstract: 
The biological mechanisms underlying cancer cell motility and invasiveness remain unclear, 
although it has been hypothesized that they involve some type of epithelial-mesenchymal 
transition (EMT). Here we show that human cancer cells express in vivo a precise multi-cancer 
invasion-associated gene expression signature characterized by the prominent presence of 
collagen COL11A1 and thrombospondin THBS2. The signature is present in the expression of 
all solid tumor datasets that we analyzed and includes numerous EMT markers, among them the 
transcription factor Slug, fibronectin, and α SMA. Using xenograft models of human cancer cells 
in immunocompromised mice and profiling the harvested tumors separately with species specific 
probes, we found that human, but not mouse, cells express most of the genes of the signature and 
Slug is the only upregulated EMT-inducing transcription factor. Taken together with the 
presence of the signature in many publicly available datasets, our results suggest that this 
Slug-based EMT signature is produced by the cancer cells themselves in multiple cancer types, 
including even nonepithelial cancers such as neuroblastoma. Furthermore, we found that the 
presence of the signature in human xenografted cells was associated with a downregulation of 
adipocyte markers in the mouse tissue adjacent to the invasive tumor, suggesting contextual 
microenvironmental interactions when the cancer cells encounter adipocytes, as previously 
reported. The known and consistent gene composition of this cancer EMT signature, particularly 
when combined with simultaneous analysis of the adjacent microenvironment, provides unique 
opportunities for shedding light on the underlying mechanisms of cancer invasiveness as well as 
identifying potential diagnostic markers and targets for metastasis-inhibiting therapeutics.    
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Introduction 
It has been hypothesized [1-3] that cancer cells become invasive and migratory by undergoing 
some type of epithelial-mesenchymal transition (EMT). Each type of EMT is assumed to be 
orchestrated by different unknown combinations of multiple interacting transcription factors and 
signaling pathways. A set of genes comprising an “EMT core signature” was recently derived [4] 
after triggering EMTs in different ways and observing the resulting shared changes in gene 
expression. However, the details of the specific types of EMT associated with cancer invasion 
remain elusive. 
 
A precise multi-cancer gene expression signature involving a set of many genes, most of them 
being EMT markers coordinately overexpressed only in a subset of malignant samples that have 
exceeded a particular staging threshold specific to each cancer type was recently identified [5].  
The signature is present in numerous publicly available datasets from multiple cancer types from 
all solid tumor types that we tried, including nonepithelial cancer such as neuroblastoma and 
Ewing's sarcoma but not in leukemia (a few examples of heat maps are shown at 
www.ee.columbia.edu/~anastas/nat_prec/supp ). Among the overexpressed genes are the EMT-
inducing transcription factor Slug (SNAI2), various collagens and proteinases, α-SMA, 
fibronectin, fibroblast activation protein, and many extracellular matrix glycoproteins, suggesting 
fibroblastic nature after passing through a Slug-based EMT. The signature, however, is not of a 
general fibroblastic nature, but rather has its own special characteristics, one of which is that 
genes COL11A1, THBS2 and INHBA have a prominent presence in all cases, and they are 
strongly co-expressed with a remarkably smooth continuous transition [5]. We identified 
collagen COL11A1 as a reliable proxy for the signature: in each solid tumor dataset that we tried, 
the list of genes whose expression is most correlated with that of COL11A1 consistently includes 
the other genes of the signature at the top, with the only exception of glioblastoma in which 
COL11A1 is not as prominently co-expressed with the other genes, though the signature is still 
present otherwise. Notably, E-cadherin (CDH1) is not downregulated at least at the mRNA level. 
Furthermore, the signature contains numerous other EMT-associated genes. Table 1 shows a list 
of the 64 genes corresponding to the 100 most overexpressed probe sets, as we previously 
reported [5], of the signature. Highlighted by bold typeface among these 64 are 20 known EMT-
associated genes, 17 coming from the list of 91 upregulated “EMT core signature” [4] genes 
(COL5A2, FAP, POSTN, COL1A2, COL3A1, FBN1, TNFAIP6, MMP2, GREM1, BGN, 
CDH11, SPOCK1, DCN, COPZ2, THY1, PCOLCE, PRRX1) plus the obvious EMT markers 
SNAI2, FN1, ACTA2. Four additional genes (underlined but not bold in Table 1), PDGFRB, 
SPARC, INHBA, COL6A2, have also been reported as EMT-related [6], for a total of 24 EMT 
factors. Even without including these additional seven genes, the P value of encountering 17 out 
of 64 genes taken from the list of the 91 EMT core signature genes is 2×10
-22
. Therefore, this 
fibroblastic signature is the result, at least in part, of an EMT.  
 
The initiation of the signature overexpression only after reaching a particular cancer-type-
specific stage suggests a biological mechanism associated with cancer invasion, but the nature of 
this mechanism remained unclear. Given the heterogeneity of cells in tumors, it could reflect the 
superposition of several mechanisms. Among other possibilities, the fibroblast-like cells 
producing the signature could be derived from multiple sources, such as the bone marrow, the 
local stroma, or the cancer cells after undergoing an EMT. A fundamental question, therefore, is 
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which among the genes of the signature are expressed by the cancer cells and which are 
expressed by the adjacent microenvironment. Relatedly, we had observed [7] a striking similarity 
between the set of genes in the signature and a subset of the genes that are known to be lower 
expressed when mouse embryonic fibroblasts are reprogrammed into induced pluripotent stem 
cells [8]. Because it is known [9] that a mesenchymal-epithelial transition (MET) is part of the 
reprogramming of mouse fibroblasts into stem cells, we reasoned that, conversely, the signature 
may correspond to some kind of EMT-related transition from a stem-like state to a fibroblast-like 
state used in early embryogenesis. Therefore, we hypothesized  [7] that most of the genes in our 
signature are expressed from cancer stem cells (CSSs) passing through some type of  EMT. 
Furthermore, because of the prominent presence of inhibin-A (INHBA) in the signature, we 
hypothesized that activin A (INHBA dimer) signaling may be responsible for the signature.  
 
To test these two hypotheses, we used xenograft models implanting human cancer cell lines into 
NCR nude mice. We used NGP neuroblastoma cells lines, as we had had prominently found the 
signature in neuroblastoma publicly available datasets (as shown in the heat map at 
www.ee.columbia.edu/~anastas/nat_prec/supp/heatmap.neuroblastoma.pdf ), even though it is a 
nonepithelial cancer, as confirming the signature in vivo in such tumors could shed further light 
on the specific EMT-like biological mechanisms. Some of the implanted cancer cell lines were in 
their original form, some were engineered to express INHBA, and some were engineered to 
express the activin antagonist follistatin (FST). Each of the resulting growing tumors was 
harvested and profiled for gene expression twice using human and mouse microarrays separately. 
Our results validated the first hypothesis, but not the second: The vast majority of the genes of 
the signature were found in human, but not mouse, cells, and their presence was independent of 
any transfections, indicating that activin signaling does not play a causal role.  
 
The presence only in human cells of coordinately expressed genes of the same previously 
identified signature [5] indicates that the cancer cells themselves undergo an EMT. Furthermore, 
the continuity of the fibroblastic transition signature (Figure 1) suggests that it may reflect a 
dynamic and reversible process. Its potential reversal is consistent with the possibility that it is a 
requirement for all metastases, even though the signature is only observed in a subset of high-
stage extracted samples.  
 
Results and Discussion     
We found very different expression levels (Figure 2) for most genes in human and mouse, 
suggesting that cross-species hybridization is minimal, which was confirmed with real-time PCR 
(see Materials and Methods). Using COL11A1 as a proxy [5], we ranked the 18 samples 
accordingly and investigated if most of the EMT markers of the signature were co-expressed 
with COL11A1. We found that this was indeed the case in human cells only. For example, 
Figures 2A-B show color-coded scatter plots in human and mouse of the 18 samples for the 
expression of Slug (SNAI2) in terms of the expression of the main genes of the fibroblastic 
transition signature, COL11A1 and THBS2 (same genes as in the scatter plots of Figure 1) 
demonstrating that this co-expression is clearly present in the human cells, but absent in the 
mouse cells.  Specifically, seven samples had high or intermediate levels of co-expressed genes 
in the human cells, while the remaining 11 have relatively lower levels.  
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Based on this partition, we identified 398 significantly (both Q < 0.05 and FC > 2) up-regulated 
genes, 29 among which (COL11A1, THBS2, COL5A2, COL5A1, VCAN, COL1A1, COL3A1, 
FN1,SULF1, FBN1, ASPN, SPARC, CTSK, MMP2, BGN, LUM, LOXL2, COL6A3, TIMP3, 
CDH11, SERPINF1, EDNRA, ACTA2, PDGFRB, SNAI2, LGALS1, GLT8D2, NID2, PRRX1) 
belong to the set of 64 genes of the fibroblastic transition signature in Table 1 (P = 10
-27
), as well 
as VIM (vimentin). The presence in this list of SNAI2 (Slug), ACTA2 (α-SMA), FN1 
(fibronectin), VIM (vimentin), together with many of the other EMT markers mentioned above, 
indicates that some human cancer cells underwent EMT. Other EMT-inducing transcription 
factors (Snail, Twist, ZEB1, ZEB2, SIP1, FOXC2) were not upregulated (Figure 2C), while the 
upregulation of SNAI2 (Figure 2A) was very significant (Q < 3×10
-4 
and FC = 5.22).  
 
The heat map in Figure 3 shows the co-expression of the above 29 significantly upregulated 
genes. INHBA, the third prominent gene of the signature in addition to COL11A1 and INHBA, is 
not included in the list, because its expression was manipulated by the transfections with 
consistent results. Furthermore, as shown in the heat map, the transfection of cancer cells with 
either INHBA (labeled I) or FST (labeled F) did not have any effect on the presence of the 
signature. Precisely these same 29 genes are used in the heat maps at 
www.ee.columbia.edu/~anastas/nat_prec/supp , suggesting that the same EMT signature may be 
expressed in all solid tumors, even in nonepithelial tumors, such as neuroblastoma and Ewing’s 
sarcoma. Therefore, our results imply the employment of a mesenchymal transition process more 
general than what EMT is assumed to be. 
 
We next analyzed the mouse microarray data to identify genes correlated with the presence of 
the cancer EMT signature in the human cells. We found 32 significantly (both Q < 0.05 and FC 
> 2) downregulated mouse genes in the presence of the human fibroblastic transition signature. 
Among them, the top two genes with the highest fold change (12.3 and 11.8 respectively) were 
the adipocyte markers adiponectin (ADIPOQ) and adipsin (CFD). We observed that these genes 
were strongly co-regulated with many other adipocyte markers, including fatty acid binding 
protein 4 (FABP4) aka aP2. This cluster of adipocyte markers whose downregulation in the 
mouse cells is strongly associated with the upregulation of the fibroblastic transition signature 
genes in human cells is also shown in the heat map of Figure 3. Many among these genes are 
known as adipocyte differentiation markers, and their downregulation is consistent with the 
finding [10] that adipocytes are dedifferentiated as they encounter adjacent invading cancer cells 
in a “vicious cycle” of interaction. 
 
The quality of “stemness” in cells appears to be closely interconnected with the ability to pass 
through transitions to and from mesenchymal characteristics. Indeed, EMT generates cells with 
properties of stem cells [11] and, conversely, MET is involved in the reprogramming of 
fibroblasts into stem cells [9].  Therefore, we speculate [7] that the cancer EMT signature 
initiates from CSCs, which may even appear spontaneously [12]. It is also possible that the 
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adipocytes of the stroma adjacent to the tumor are dedifferentiated into a mesenchymal stem cell-
like state and, together with other mesenchymal stem cells derived from the bone marrow [13] 
interact with the invading fibroblastic cancer cells in a manner that reactivates a particular early 
embryonic developmental program.  
 
Not all fibroblastic transition genes in Table 1 are upregulated in the human cells.  For example, 
PLAU (urokinase plasminogen activator) is slightly upregulated only in mouse cells consistently 
with its assumed role of being secreted by reactive stromal cells as a pro-enzyme that activates 
itself and other proteases in the presence of cancer cells. 
 
Another prominent fibroblastic transition gene that is not upregulated in human cells is MMP11 
(matrix metallopeptidase 11, aka stromelysin 3), in agreement with the hypothesis [10, 14, 15] 
that MMP11 is expressed in the adipocytes of the adjacent reactive stroma, indicating that the 
full  version of the cancer EMT signature may be stabilized by contextual microenvironmental 
signals when cancer cells encounter adipocytes triggering their dedifferentiation, apoptosis, or 
metabolism. This process may reflect a Darwinian selection mechanism, as cancer cells may not 
survive the uptake of lipid droplets [14]. The expression in cancer cells of the adipocyte enhancer 
binding protein 1 (AEBP1), a prominent gene of the signature known to bind in the promoter 
region of the adipocyte fatty-acid protein FABP4 may play an important role in that respect, as 
may also the presence of oxidative stress and TNF signaling suggested by the presence of 
TNFAIP6 and C1QTNF3 in the signature. 
 
The hypothesis that the EMT signature is triggered by adipocytes is consistent with the facts [5] 
that in breast cancer the signature overexpression appears immediately upon reaching invasive 
stage I, while in ovarian cancer overexpression appears only when the tumor is already well into 
stage III as in omental metastasis, because ovarian cancer initially progresses by disseminating 
locally across mesothelial surfaces and probably carried by the physiological movement of 
peritoneal fluid to the peritoneum and omentum, a fatty structure  [16].  
 
Many among the top genes of the cancer EMT signature (Table 1) have previously been 
individually identified as associated with metastatic potential in cancer. Such associations can 
now largely be explained by the fact that these genes are expressed by the cancer cells 
themselves undergoing an EMT expressing a precise gene signature. The known composition of 
the signature, particularly when combined with its separation in a species-specific manner in 
xenograft models, provides multiple and unique opportunities for understanding the underlying 
biological mechanisms and identifying prognostic markers and potential targets for metastasis-
inhibiting therapeutics. 
 
Materials and Methods  
Tumor Implantation 
An inoculum of 10
6
 NGP neuroblastoma cells containing FUW-Luciferase plasmid (kindly 
donated by Dr. Adolfo Ferrando) suspended in 0.1 mL of phosphate-buffered saline (PBS) was 
injected into the left kidney of 18 mice. The NGP cell line was originally obtained from Garrett 
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Brodeur, Children's Hospital of Philadelphia. All cells were authenticated by short tandem repeat 
profiling analysis. Some of the implanted cells had previously been stably co-transfected with 
either FST-pReceiver-Lv105 or INHBA- pReceiver-Lv105 (GeneCopoeia; Rockville, MD). 
Seven mice were implanted with INHBA co-expressing NGP cells, six with FST and five with 
control NGP cells. 
 
Harvesting of Specimens  
Mice were sacrificed when estimated tumor weight reached 1.5 g followed by collection of 
contralateral kidney and tumor. Tumor tissue was snap frozen for RNA isolation. 
 
Microarrays and probes preparation 
15 Ag of biotinylated cRNA prepared as recommended using Affymetrix GeneChip 3' IVT 
express kit (Affymetrix, Santa Clara, CA) from RNA that was  isolated and was hybridized to 
HG-U133A 2.0 and 430 A2.0 Gene Chips (Affymetrix, Santa Clara, CA) according to 
Affymetrix recommendations (GeneChip Hybridization, Wash, and Stain Kit). The samples 
were scanned with Affymetrix Gene Chip Scanner 3000. After scanning, expression values for 
each gene were determined using Affymetrix Gene Chip software version 4.0. 
 
RNA isolation and semiquantitative reverse transcription-PCR 
Total RNA was isolated from tumors using Qiagen miRNeasy mini kit (Qiagen , Germantown, 
MD) followed by reverse transcription using SuperScript First-Standard synthesis System for 
RT-PCR from Invitrogen according to manufacture recommendations (Carlsbad, CA USA). 
Relative expression of human versus mouse COL11A1 (Hs00266273_m1,Ms00483387_m1) 
genes in tumor xenografts were examined by RT-PCR.  Products were detected by Hot Start-IT 
Probe qPCR Master Mix from USB Affymetrix (Santa Clara, CA) according to manufacture 
instructions and analyzed by Stratagene Mx3005p real time PCR machine. After scanning, 
expression values for genes were determined using MxPro 410 (Agilent Technologies, Inc., 
Santa Clara, CA). To correct for sample variations in RT-PCR efficiency and errors in 
quantitation, analysis of human HPRT, CYC, GAPD and mouse GAPD, ACTB, GUSB, 
expression was used.  
 
Microarray dataset 
The data set, corresponding to 18 tumors profiled separately with human and mouse microarrays, 
will be available from the GEO database under accession number to be assigned. Data were 
RMA normalized using the Bioconductor open source software.  
 
Differential expression analysis 
We regrouped the 18 samples, according to the expression level of human COL11A1, into 7 
samples with high or intermediate COL11A1 expression values, and 11 with low COL11A1 
expression values. Based on this partition, we performed differential expression analysis using 
significance analysis of microarrays (SAM) [17], implemented in the Bioconductor package 
samr. We define the significantly differentially expressed gene as those having both a Q-value 
less than 0.05 and a fold-change greater than 2.  
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Figure Legends and Figures 
 
 
Figure 1: Color-coded scatter plots for the coexpression of the EMT inducing transcription 
factor Slug (SNAI2) with the main signature genes COL11A1 and THBS2,  indicating 
the strong co-expression as well as continuity of the passing of cancer cells through a 
Slug-based EMT in solid tumors, and the total absence of the co-expression of these 
genes otherwise. A, B and C, plots from three solid tumor datasets. D, plot from a 
leukemia dataset. 
 
Figure 2: Color-coded scatter plots in human and mouse of the 18 samples for the expression of 
the EMT inducing transcription factor Slug (SNAI2) in terms of the expression of the 
main signature genes COL11A1 and THBS2. A, demonstration that this co-expression 
is present in the xenografted human cells. B, demonstration that this co-expression is 
absent in the peritumoral mouse cells.  C, Bar diagram indicating that other EMT 
inducing transcription factors are not co-expressed. 
 
Figure 3: Heat map combining human and mouse genes. The 29 human genes include many 
EMT factors and were found to be significantly co-expressed in the cancer cells. 
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Figure 2 
 
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
24
3.
1 
: P
os
te
d 
13
 A
ug
 2
01
1
11 
 
 
Figure 3 
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Tables  
Table 1:  Top genes overexpressed in the fibroblastic transition signature (see text for 
designation of genes with boldface and underline)  
 
 
Rank Probe set Gene Rank Probe set Gene 
1 37892_at COL11A1 33 202998_s_at LOXL2 
2 203083_at THBS2 34 201438_at COL6A3 
3 217428_s_at COL10A1 35 209596_at MXRA5 
4 221729_at COL5A2 36 213764_s_at MFAP5 
5 210511_s_at INHBA 37 204589_at NUAK1 
6 213909_at LRRC15 38 217762_s_at RAB31 
7 212488_at COL5A1 39 201150_s_at TIMP3 
8 204619_s_at VCAN 40 221541_at CRISPLD2 
9 209955_s_at FAP 41 205422_s_at ITGBL1 
10 202311_s_at COL1A1 42 207173_x_at CDH11 
11 203878_s_at MMP11 43 213338_at TMEM158 
12 210809_s_at POSTN 44 202363_at SPOCK1 
13 202404_s_at COL1A2 45 204051_s_at SFRP4 
14 202952_s_at ADAM12 46 202283_at SERPINF1 
15 215076_s_at COL3A1 47 209335_at DCN 
16 215446_s_at LOX 48 219655_at C7orf10 
17 210495_x_at FN1 49 219561_at COPZ2 
18 201792_at AEBP1 50 219773_at NOX4 
19 212353_at SULF1 51 204464_s_at EDNRA 
20 202766_s_at FBN1 52 200974_at ACTA2 
21 219087_at ASPN 53 202273_at PDGFRB 
22 200665_s_at SPARC 54 61734_at RCN3 
23 202450_s_at CTSK 55 213139_at SNAI2 
24 206026_s_at TNFAIP6 56 220988_s_at C1QTNF3 
25 222020_s_at HNT 57 205713_s_at COMP 
26 206439_at EPYC 58 201105_at LGALS1 
27 201069_at MMP2 59 213869_x_at THY1 
28 205479_s_at PLAU 60 202465_at PCOLCE 
29 218469_at GREM1 61 209156_s_at COL6A2 
30 201261_x_at BGN 62 221447_s_at GLT8D2 
31 213125_at OLFML2B 63 204114_at NID2 
32 201744_s_at LUM 64 205991_s_at PRRX1 
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